secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001140361-25-019153
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy
--------------------------------------------------------------------------------

- Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.
- Cash and equivalents $41.8M; management expects runway into Q2 2026.
- License revenue from Viatris was $4.4M, up from $1.7M YoY, primarily R&D reimbursement.
- OPGx-LCA5 Phase 1/2 data at ARVO show durable efficacy at 12 months; pediatric cohort enrollment started.
- Topline data for LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials expected mid-2025 and H1 2025, respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/0001140361-25-019153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-019153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer